Top Story

Screening with flexible sigmoidoscopy reduces mortality risk

August 21, 2017

Contrary to current guidelines, new research published in Annals of Internal Medicine suggests that colorectal cancer screening with flexible sigmoidoscopy reduces risk for death, indicating that existing recommendations need to be reassessed.

“The 2016 U.S. Preventive Services Task Force (USPSTF) evidence report on colorectal cancer screening concluded that no colorectal cancer screening methods reduce all-cause mortality,” Andrew W. Swartz, MD, from the Yukon-Kuskokwim Delta Regional Hospital in Alaska, and colleagues wrote. “This conclusion was partially based on a meta-analysis of four randomized trials that compared flexible sigmoidoscopy screening with no screening. The meta-analysis aggregated results from the two age cohorts of one of the trials — the NORCCAP (Norwegian Colorectal Cancer Prevention) study — as if these cohorts were a single trial. Aggregation of outcomes that have markedly different event rates, screening-control ratios, or both can create a Simpson paradox.”

In the Journals Plus

Extensive cancer screening may not benefit patients with unprovoked venous thromboembolism

August 21, 2017
Extensive cancer screening for individuals who experience unprovoked venous thromboembolism initially may detect more cancer cases than a limited occult screening…
FDA News

FDA grants orphan drug designation to SY-1425 for acute myeloid leukemia

August 21, 2017
The FDA granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia, according to the drug’s manufacturer. SY-1425 (Syros…

Trump signs FDA Reauthorization Act of 2017 into law

August 21, 2017
President Donald J. Trump recently signed the FDA Reauthorization Act of 2017 into law. The

The US Oncology Network boot camp provides expertise, gathers feedback about value-based care

August 21, 2017
The US Oncology Network recently held its second annual boot camp focusing on value-based care. More than 100 stakeholders and leaders met for the intensive 2-day…
More Headlines »

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Meeting News

VIDEO: Pembrolizumab benefits patients with HER-2–negative breast cancer

July 31, 2017
More »
Resource Centers


Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Current Issues
View the Current Issue
HemOnc Today